Biogemma is a European plant biotechnology company founded in 1997 by seed companies and French field crop producers. Its original mission was to create new genetic variability via GM traits to be exploited by its shareholding companies. With the arrival of the plant genomics boom in 1999-2000, Biogemma’s role was enlarged to include the development of genomics tools for its main target species and the production of informative markers for genes identified in the genomics projects. These marker- trait associations support the marker-assisted breeding programmes of their shareholders. Today, Biogemma has around 80 staff and 4 sites. Research programmes focus on maize (corn), wheat, oilseed rape (canola) and sunflower.

Company details

5 Rue Saint-Germain l`Auxerrois , Paris , 75001 France
View in map

Find locations served, office locations, manufacturers and our distributors.

Business Type:
Industry Type:
Market Focus:
Globally (various continents)

This company also provides solutions for other industrial applications.
Please, visit the following links for more info:



Biogemma’s mission is to discover or acquire genes and technologies which control the expression of traits of commercial interest to their shareholders.

These technologies and genes are used:

  • To generate new genetic variability via GM Trait development
  • To validate novel alleles or allelic combinations of those genes to be exploited using molecular assisted breeding in our shareholders programs

In order to achieve its mission, Biogemma works with partners all around the World helping us to maintain a strong innovative culture. Biogemma’s innovation pipeline is focused on delivering technology and products to improve shareholders’ competitiveness.

To fulfil its mission of creating new variability, Biogemma has developed an efficient transgenic pipeline. Gene constructs are built in proprietary vectors and transformed into maize and wheat using either FTO or proprietary technologies. The aim is to validate genes in our species of interest within 3 to 4 years and to prepare transgenic events for commercial deregulation.

At the same time, marker-gene trait association are transferred to our shareholders for use on their molecular breeding programs.

Today, Biogemma has around 80 staff and 4 sites. Research programmes focus on maize (corn), wheat, oilseed rape (canola) and sunflower.

The Biogemma headquarters is based in Paris (FR), where we have our main support services in human resources and finance.

The main cereal genomics and transgenesis laboratory is based near Clermont-Ferrand (FR). It houses around 55 of our staff and in addition to the cereal programmes in maize and wheat, it is home to our central genomics platform, with access to state-of-the-art transcriptome and next-generation sequencing technologies as well as our bioinformatics service.

The oilseed research laboratory near Toulouse (FR) has around 20 staff and is home to our genetics and genomics programmes in sunflower and oilseed rape as well as our plant pathology platform.

The field trial station in Ames (USA) is dedicated to the evaluation of experimental transgenic cereals across the USA.

“A collaborative strategy”

Developing new genetic variability from a scientific observation to a ready to market product is a long and costly process. We exploit a number of powerful molecular technology and phenotyping platforms, around genomics, genetics, bioinformatics and transgenesis. This broad in-house pipeline generates high-added value tools, and any additional information on our most important traits helps improve the efficiency of our process.

Biogemma is very much in favour of collaborative projects. They bring knowledge and skills to improve our choice of targets and give our partners a stake in adding value to their results. We are and have been involved in numerous collaborations, ranging from almost exclusively scientific work in initiatives like the French Génoplante programme, and its latest form the GIS Green Biotechnology, or EU research projects, to targeted collaborations with biotech companies worldwide aimed at commercial development.